Stephen Bloch Sells 85,062 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 85,062 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $71.44, for a total value of $6,076,829.28. Following the transaction, the director directly owned 980,073 shares in the company, valued at approximately $70,016,415.12. This represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Liquidia Stock Performance

NASDAQ LQDA opened at $68.65 on Thursday. The company has a market cap of $6.11 billion, a P/E ratio of 490.39 and a beta of 0.58. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The business’s 50 day moving average price is $51.76 and its 200-day moving average price is $41.76. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $73.22.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business’s quarterly revenue was up 4187.1% on a year-over-year basis. Sell-side analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on LQDA shares. Wells Fargo & Company boosted their target price on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Raymond James Financial reissued a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. HC Wainwright boosted their target price on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, June 5th. BTIG Research increased their target price on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $60.29.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia in the fourth quarter valued at about $25,000. Covestor Ltd raised its holdings in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Liquidia in the third quarter valued at about $30,000. FNY Investment Advisers LLC bought a new stake in shares of Liquidia in the third quarter valued at about $34,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Liquidia in the second quarter valued at about $25,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).